A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 29 Dec 2016 Status changed from recruiting to active, no longer recruiting.